Evaluation of Serum Integrin αvβ3 & Vitronectin in the Early Diagnosis of Breast Cancer
| Autor: | Amal Fawzy, Omnia E Ismael, Hala O El-Mesallamy, Abdullah F Radwan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
030213 general clinical medicine medicine.medical_specialty Alpha-v beta-3 Integrin Breast Neoplasms Gastroenterology General Biochemistry Genetics and Molecular Biology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Internal medicine Biomarkers Tumor medicine Humans Vitronectin Stage (cooking) Lymph node Early Detection of Cancer biology business.industry Mucin-1 Middle Aged Integrin alphaVbeta3 Prognosis medicine.disease Fibroadenoma medicine.anatomical_structure ROC Curve chemistry biology.protein Biomarker (medicine) Female business |
| Zdroj: | Clinical Laboratory. 65 |
| ISSN: | 1433-6510 |
| DOI: | 10.7754/clin.lab.2019.181219 |
| Popis: | BACKGROUND This study aimed to evaluate the relationship of serum vitronectin and integrin alpha V beta 3 (αvβ3) levels with various clinicopathological parameters of breast cancer and to assess the diagnostic value of these markers alone or in combination with the conventional breast cancer biomarker CA15.3. METHODS This study included 50 early diagnosed stage I - II primary breast cancer patients, 20 patients with fibroadenoma benign lesions, and 20 apparently normal healthy controls. Integrin αVβ3, vitronectin, and CA15.3 levels were measured using ELISA technique. RESULTS Serum levels of integrin αVβ3 and vitronectin were significantly higher in the malignant group than those in the benign group and the control group with (p < 0.001). Significant positive correlation between integrin αvβ3 and vitronectin concentrations was found. Both markers showed significant statistically difference with lymph node, histological grade, tumor stage, and tumor size (p < 0.05). Integrin αvβ3 exhibited the highest sensitivity (70%) and specificity (68%), then vitronectin with 67% and 68%, respectively, followed by CA15.3 showing the least sensitivity and specificity (65% and 62%, respectively). All assessed parameters revealed comparable area under the receiver-operating characteristic curve (AUC) 95% confidence interval (CI) range of 0.581 - 0.822. CONCLUSIONS Integrin αvβ3 is a promising biomarker alone or in combination with vitronectin and CA15.3 for diagnosis and prognosis of early stage breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|